The arsenal of therapeutics for brain tumors is limited by the relative impermeability of the blood-brain and blood-tumor barriers. In physiologic states, the blood-brain barrier (BBB) serves a protective role by passively and actively extruding neurotoxic compounds. However, this function limits the penetrance of therapies into the tumor microenvironment (TME). Advances in focused ultrasound (FUS) technology provide a method of bypassing the BBB through ultrasound frequency to transiently permeabilize the BBB and BTB. Concomitant delivery of tumor therapeutics has allowed for previously impermeable therapeutics to reach the TME. This review details the advances in FUS in both preclinical and clinical models, focusing on its safety profile. We then turn the discussion toward future directions in FUS-mediated therapies for brain tumors. Keywords: Microbubble-enhanced focused ultrasound, blood-brain barrier, blood tumor